Daiwa Securities Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Daiwa Securities Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-96	Closed	-$2K	–	1264
2025 Q4	$2K	Buy	+96	New	+$1.22K	﹤0.01%	1303
2023 Q4	–	Sell	-69	Closed	-$1K	–	1341
2023 Q3	$1K	Hold	69	–	–	﹤0.01%	1246
2023 Q2	$1K	Hold	69	–	–	﹤0.01%	1269
2023 Q1	$3K	Hold	69	–	–	﹤0.01%	1183
2022 Q4	$3K	Hold	69	–	–	﹤0.01%	1191
2022 Q3	$4K	Hold	69	–	–	﹤0.01%	1174
2022 Q2	$3K	Hold	69	–	–	﹤0.01%	1199
2022 Q1	$5K	Hold	69	–	–	﹤0.01%	1172
2021 Q4	$5K	Hold	69	–	–	﹤0.01%	1195
2021 Q3	$4K	Buy	69 +31	+82%	+$1.53K	﹤0.01%	1192
2021 Q2	$2K	Hold	38	–	–	﹤0.01%	1139
2021 Q1	$2K	Hold	38	–	–	﹤0.01%	1141
2020 Q4	$2K	Sell	38 -73	-66%	-$3.21K	﹤0.01%	1120
2020 Q3	$5K	Hold	111	–	–	﹤0.01%	1091
2020 Q2	$6K	Hold	111	–	–	﹤0.01%	1098
2020 Q1	$6K	Hold	111	–	–	﹤0.01%	1091
2019 Q4	$7K	Sell	111 -13	-10%	-$806	﹤0.01%	1086
2019 Q3	$7K	Hold	124	–	–	﹤0.01%	1052
2019 Q2	$10K	Hold	124	–	–	﹤0.01%	1057
2019 Q1	$12K	Buy	124 +19	+18%	+$1.7K	﹤0.01%	1024
2018 Q4	$7K	Hold	105	–	–	﹤0.01%	1026
2018 Q3	$9K	Hold	105	–	–	﹤0.01%	1047
2018 Q2	$12K	Hold	105	–	–	﹤0.01%	1041
2018 Q1	$8K	Buy	+105	New	+$8.08K	﹤0.01%	1047

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Daiwa Securities Group's ENTA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Enanta Pharmaceuticals (ENTA) in Q1 2026, closing a stake of 96 shares — an estimated $2K sold.

Daiwa Securities Group first reported a position in ENTA in Q1 2018 and held it in 24 quarters. The position peaked at $12K in Q1 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Daiwa Securities Group reported no remaining Enanta Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Daiwa Securities Group sold 96 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2K.
Daiwa Securities Group first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 24 quarters.
Daiwa Securities Group's Enanta Pharmaceuticals position peaked at $12K in Q1 2019.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.